drugset / Trial / NCT04172987
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Timeline
- Start
- 2020-02-26
- Primary completion
- 2021-02-09
- Completion
- 2021-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Norgestimate | Small molecule | 0.25 mg | Oral |
| Subject | Tirzepatide | Peptide | 5 mg | Subcutaneous |
| Subject | ethinyl estradiol | Small molecule | 0.035 mg | Oral |
Indications
No indication recorded.